NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $2.96 -0.01 (-0.34%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.92▼$3.1650-Day Range$2.61▼$12.1852-Week Range$2.54▼$14.22Volume856,554 shsAverage Volume496,334 shsMarket Capitalization$74.98 millionP/E RatioN/ADividend YieldN/APrice Target$20.21 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verastem alerts: Email Address Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside582.9% Upside$20.21 Price TargetShort InterestBearish11.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 15 Articles This WeekInsider TradingSelling Shares$107 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.14) to ($3.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector383rd out of 936 stocksPharmaceutical Preparations Industry182nd out of 436 stocks 4.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verastem's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.19% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 77.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 1.8 News and Social Media Coverage News SentimentVerastem has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Verastem this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($4.14) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesJuly 26 at 3:50 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) PT Lowered to $7.00July 24 at 9:43 AM | americanbankingnews.comStockNews.com Downgrades Verastem (NASDAQ:VSTM) to SellJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 24 at 5:31 AM | msn.comVerastem Oncology slumps 26%, prices $55M offeringJuly 24 at 12:30 AM | markets.businessinsider.comVerastem Oncology Announces Pricing Of $55.0 Mln Offering Of Common Stock, WarrantsJuly 24 at 12:30 AM | finance.yahoo.comVerastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded WarrantsJuly 23, 2024 | marketwatch.comVerastem Shares Drop 25% After Public Offering NewsJuly 23, 2024 | businesswire.comVerastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded WarrantsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 20, 2024 | finance.yahoo.comInflaRx NV (IF0.DU)July 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMJuly 10, 2024 | globenewswire.comVerastem, Inc. Investors: Company Investigated by the Portnoy Law FirmJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMJune 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verastem, Inc. – VSTMJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMJune 22, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMSee More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$20.21 High Stock Price Target$36.00 Low Stock Price Target$7.00 Potential Upside/Downside+582.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.95% Return on Assets-65.83% Debt Debt-to-Equity Ratio1.60 Current Ratio4.40 Quick Ratio4.40 Sales & Book Value Annual Sales$2.60 million Price / Sales28.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.30Miscellaneous Outstanding Shares25,330,000Free Float24,769,000Market Cap$74.98 million OptionableOptionable Beta0.19 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 63)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO and Principal Accounting & Financial Officer Comp: $1.42MMr. Richard H. Aldrich M.B.A. (Age 70)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 48)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 66)Chief Scientific Officer Comp: $238.18kMr. Nate SanburnSenior Vice President of Corporate Development & External EngagementDr. Hagop Youssoufian M.D. (Age 67)M.Sc., Ph.D., Head of Medical Strategy More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMXOMANASDAQ:XOMACodexisNASDAQ:CDXSRigel PharmaceuticalsNASDAQ:RIGLAchieve Life SciencesNASDAQ:ACHVView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 68,224 shares on 7/26/2024Ownership: 0.269%Daniel CalkinsSold 7 sharesTotal: $18.34 ($2.62/share)Daniel CalkinsSold 28 sharesTotal: $88.20 ($3.15/share)Vanguard Group Inc.Bought 10,678 shares on 5/10/2024Ownership: 4.587%Daniel CalkinsSold 6 sharesTotal: $65.22 ($10.87/share)View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM stock has decreased by 63.6% and is now trading at $2.96. View the best growth stocks for 2024 here. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by $0.10. When did Verastem's stock split? Verastem's stock reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Verastem's major shareholders? Verastem's top institutional investors include Bank of New York Mellon Corp (0.27%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE) and SCYNEXIS (SCYX). This page (NASDAQ:VSTM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.